


Study of Beam Dynamics in JINR Phasotron

L.Onischenko, S. Kostromin, A. Chesnov, S. Shirkov

Joint Institute for Nuclear Research, Dubna






I.V. Kurchatov and
V.P. Dzhelelov

Synchrocyclotron “Phasotron”

The First Accelerator in Dubna

Constructed in frames of the Soviet Atomic Project,
commissioned in 1949, still in operation



M. G. Meshcheryakov

Machine parameters:

- Protons
- 660 MeV
- 3 μ A –
extraction




Research program:


- ✓ Muon-catalysis
- ✓ Pion & muon
physics
- ✓ Nuclear
physics

Main application:
Cancer therapy

B-mean [Tesla]





Magnetic field via



3

Beam dynamics calculation




Acceleration of 2000 particles (without space charge effects) from radii of ~ 100 cm till to entrance in the extraction system

Initial data taken from calculations of beam dynamics during first 3000 turns after ions source taken in account effects of the space charge


1500 turns from the bunch start

One synchrotron oscillation: ~ 600 turns - $\sim 30\mu\text{s}$




Changing of the revolution frequency of the central particle


40 000 turns to get the
extraction system





Changing of the revolution frequency of the
central particle

Vertical motion amplitude
 $\pm 10\text{mm}$








Frequency of the betatron oscillations basing of the analysis of the measured magnetic field map



Vertical betatron frequency for the equilibrium accelerated particle in during modeling of the acceleration



Extraction system scheme of JINR Phasotron P-peeler, R-regenerator, I, II, III, IV – sections of the extraction channel




Magnetic field of the peeler & regenerator (1) and its gradient (2)

Параметры элементов систем заброса и вывода.

Параметры	ЖТС		Ферромагнитные секции системы вывода			Возбудитель	Регенератор
	1	2	3	4	5	6	7
$\varphi_1, ^\circ$	1.0	9.8	20.0	25.2	36.5	348.0	50.7
$\varphi_2, ^\circ$	9.8	18.7	24.7	35.8	44.7	353.7	56.4
$\Delta B, \text{kG}$	-4.7	-4.5	-4.0	-5.4	0.0	-2.48	2.16
$\text{dB/dX}, \text{kG/cm}$	0.15	0.03	-0.1	-0.1	1.0	-0.31	0.27
Гор. апертура, см	1.8	1.8	2.2	2.6	5.0	11.0	13.0
$R_1, \text{см}$	275.6	276.2	279.5	282.3	291.0	272.5	274.5
$R_2, \text{см}$	276.2	279.0	282.0	290.5	299.0	272.5	274.5


В Таблице R_1, R_2 – радиусы средин апертур элементов на входе и выходе по движению пучка. Магнитные поля элементов указаны для средин их апертур.


Pr [мрад]




Particles positions at the R-Z-plane at the entrance in to extraction system

Particles positions at the radial phase-plane at the entrance into the extraction system








Particles energy distribution at the entrance to the extraction system



2σ-rms-beam-envelopes inside Phasotron extraction channel



Профили пучка в точке А (см. Рис 1) и на входе в магнит СП-35 полученные расчетным способом



Автографы пучка в точке А (см. Рис 1) и на входе в магнит СП-35 экспериментально полученные [3] при запуске Фазотрона ОИЯИ

Beam portraits at the entrance to the extraction channel are obtained.

The beam extraction efficiency is about **40%**.

Beam tracking inside the channel carried out.

Calculated beam transverse parameters are in agreement with **~20%** accuracy with the experimental data.

Developed code can be used for optimization of JINR Phasotron extraction system or to study the beam dynamics in other synchrocyclotrons.

IBA Superconducting Synchrocyclotron for Proton Therapy: Central Region Design

E. Pearson, W. Kleeven, P. Verbruggen, V. Jongs, IBA, Belgium (www.iba-worldwide.com)
M. Conjat (www.aima.fr)

Introduction



The first IBA superconducting (S2C2) is being developed in response to the need for a more compact and low cost proton therapy product. The S2C2 is a 2.5 m diameter of diameter 2.5 m and an extracted beam current of 20 nA. The magnet has a rotational speed of 1000 rpm and a maximum magnetic field of 1.5 T. The central region design is of crucial importance to the optical quality of the beam and so accurate design is mandatory.



Capture

Protons can be more compact than electrons, however, there is also a limit to the beam intensity. The reason is that protons are captured during the acceleration phase of the frequency modulation. The conditions at injection time therefore have a significant effect on acceptance and capture.

Capture



http://mevion.com/triniobium-core

Входящие - serge.kostromin...

mevion s250 - Поиск в Google

The Technology

About Us News & Events Careers Contact Us

THE SCIENCE **THE TECHNOLOGY** **THE SYSTEM**

MEVION
HIGH ENERGY CANCER CARE
medical systems



THE TECHNOLOGY

■ **TRINIObium CORE™** ■ **DIRECTDOSE™** ■ **CLINICAL SYSTEMS**

"Throughout my career, I have been convinced that proton therapy adoption was limited by the enormous size and complexity of the proton source and associated beam transport and delivery systems. We have developed technology that simplifies proton therapy installations, making them comparable to conventional radiation therapy devices. This now makes proton therapy readily available to pediatric and adult cancer patients who can benefit from this remarkable therapy." Kenneth Gall, Ph.D., Co-Founder and Chief Technology Officer

TriNiobium Core™

Mevion has designed a high-energy proton source that has dramatically reduced the size, cost, and complexity of proton acceleration; the world's first superconducting synchrocyclotron. The enabling technology is the TriNiobium Core™, an industrially used superconducting metallic compound called TriNiobium Tin (Nb_3Sn) that is at the center of the accelerator. Powered by the TriNiobium Core, this revolutionary proton accelerator is only 6 ft (1.8 m) in diameter, but can generate 250 MeV protons capable of reaching targets as deep as 32 cm. With this dramatic size reduction, the proton source is coupled to a high-precision beam delivery and shaping device, and tightly integrated with the most advanced clinical systems.

The MEVION S250 Proton Therapy System is USFDA 510(k) cleared and complies with MDD/CE requirements.



Спасибо за внимание